Takeshi Takahashi - 12 Jul 2023 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Director
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
12 Jul 2023
Net transactions value
$0
Form type
4
Filing time
14 Jul 2023, 08:55:32 UTC
Previous filing
13 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Other $0 -44,000 -100% $0.000000* 0 12 Jul 2023 Common Stock 44,000 $16.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents stock options transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP.
F2 The stock option vests in 36 monthly installments beginning on March 9, 2023.